Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...
Hosted on MSN1mon
Greenwich LifeSciences reports progress in FLAMINGO-01 trialS TAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA ...
If iPS cell lines could be derived from donors' somatic cells with an efficiency and safety profile that was comparable to ES cell lines, an opportunity exists to establish more efficient HLA ...
The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...
Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback